Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-723 in Patients With Advanced Solid Tumors
NCT05537987Phase 1Unknown
- Sponsor
- InnoCare Pharma
- Start
- Jul 2021
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zurlectrectinib in solid tumor (advanced stage), sponsored by InnoCare Pharma. Primary endpoint: Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Status: unknown.
02
Drugs
zurlectrectinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05537987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537987.